BACKGROUND Portico valve is a second-generation self-expanding repositionable system with a nitinol stent frame and bovine pericardial leaflets, which is increasingly utilized for transcatheter aortic valve replacement (TAVR) in patients with severe native aortic stenosis at high risk of conventional surgery. In this report, we describe the procedural and early clinical results from an international multicenter registry of Portico implantation in patients with degenerated aortic bioprosthesis (Portico ViV).
RESULTS 45 patients undergoing Portico ViV were included in analysis. The mean age was 79AE 7 years with STS (mortality) score of 7AE4. These procedures had mainly utilized peripheral arterial access (93%), with transesophageal echocardiogram guidance (60%) for treatment of surgical valve label size 21, >21-<25, and !25mm in 36, 38 and 27% respectively. Four (9%) of the failed surgical bioprostheses were stentless. Successful implantation was achieved in 44 (98%) cases with no malposition events or clinically-evident coronary obstruction. Post implantation valve area was 1.3 AE0.4 cm2, mean gradient of 17.1 AE 7.7 mmHg and ! moderate aortic insufficiency was observed in 3 (7%). One death (2%) related to ischemic stroke occurred within 30 days. Major bleeding and vascular complication in 5 (11%) and 1 (2%) respectively. One patient required permanent pacemaker implantation (2%).
CONCLUSIONS Results from this international multicenter registry show that Portico offers a safe and effective treatment of failed surgical bioprosthesis with an added advantage of device retrievability, resulting in low incidence of malpositioning and coronary obstruction. Additional studies and comparison with other transcatheter devices should further determine the hemodynamic and clinical performance of this device for selection of optimal treatment of high risk patients with failed surgical bioprostheses. BACKGROUND Transcatheter aortic valve implantation (TAVI) is the treatment option of choice for high surgical risk patients presenting with severe symptomatic aortic stenosis. First generation devices were limited by non-negligible TAVI-related complications including !2 paravalvular leak (PVL) and vascular complications that are predictors of mortality. As a result, newer devices have been developed to overcome these limitations. We aimed to compare procedural and clinical outcomes between contemporary and first generation devices. RESULTS 449 patients were included in the 1G, and 179 patients to the 2G. Patients in the FG were older (83.4 vs. 82.1 years, p¼0.03), of a higher risk profile (Euroscore 10 vs. 9.5, p¼0.04) with a similar gender preponderance (female: 61.2% vs. 61.4%, p¼0.79). Peri-procedurally, there was a lower incidence of major or life-threatening bleeding complications in the 2G compared to the 1G (8.4% vs. 21.4%, p<0.001) and !2 PVL (6.1% vs. 17.1%, p¼0.003) with no differences in the rates of stroke (3.3% vs. 1.8%, p¼0.23) or PPM implantation (11.2% vs. 12.7%, p¼0.6) respectively. Mortality at 30-days (3.6% vs. 1.4%, p¼0.77) and at 1-year (11.2% vs. 12.7%, p¼0.81) were similar between groups.
CONCLUSIONS This single-center retrospective study demonstrates that newer generation TAVI devices are associated with a reduction in !2 PVL and major and life-threatening bleeding events when compared to first generation devices. There were no differences in short-term mortality. Longer-term follow-up are required to determine if these short-term procedural improvements are translated into a longer-term outcome benefit. BACKGROUND Transcatheter aortic valve implantation (TAVI) is a treatment for patients with aortic stenosis deemed high risk for aortic valve replacement (AVR). Advancing age independently predictors mortality after AVR, so that most patients undergoing TAVI are elderly. This study presents UK trends in activity and outcomes for TAVI and AVR in patients aged 80 or over in the "TAVI era". (by 160%). TAVI patients were older, more likely to be female, in NYHA class IV, with prior cardiac surgery, renal, pulmonary, and ventricular dysfunction, extra-cardiac arteriopathy, and neurological disease than AVR patients (logistic EuroSCORE 23.5AE13.7 vs. 13.6AE9.5, p<0.001). 30-day mortality was 10.55% (AVRþother), 5.61% (AVRþCABG), 5.54% (TAVI), and 3.45% (AVR). Mean PLOS (days) were 17.8 (AVRþother), 14.4 (AVRþCABG), 12.6 (AVR), and 9.1 (TAVI). 1-year survival was 89.6% (AVR), 85.1% (AVRþCABG), 81.9% (TAVI), and 78.8% (AVRþother surgery). 5-year survival was 64.2% (AVR), 59.7% (AVRþCABG), 56.5% (AVRþother surgery), and 43.4% (TAVI).
METHODS
CONCLUSIONS In 2007, TAVI made up only 3% of all aortic valve interventions in patients !80 years. This had increased ten-fold to almost 30% of all aortic valve interventions by 2012. Despite increased age and risk scores, length of hospital stay was shorter, and 30-day and 1-year mortality rates were comparable with other aortic valve interventional groups.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic 
